Showing results (1411-1420 of 1,523) with videos related to

Sort By:
Pageof 153
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 11, 2022
Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA TrialMargarita Majem, Jonathan W Goldman, Thomas John, et al.
Cellular Oncology (Dordrecht, Netherlands)|January 8, 2026
Disrupting CDK9 activity suppresses triple-negative breast cancer and is enhanced by EGFR InhibitionVera E van der Noord, Ronan P McLaughlin, Jessica S Karuntu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 26, 2024
Vebreltinib for Advanced Non-Small Cell Lung Cancer Harboring c-Met Exon 14 Skipping Mutation: A Multicenter, Single-Arm, Phase II KUNPENG StudyJin-Ji Yang, Yan Zhang, Lin Wu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 20, 2024
Neoadjuvant and Adjuvant Treatments for Early Stage Resectable NSCLC: Consensus Recommendations From the International Association for the Study of Lung CancerJonathan D Spicer, Tina Cascone, Murry W Wynes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2023
Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURAJhanelle E Gray, Myung-Ju Ahn, Geoffrey R Oxnard, et al.
JTO Clinical and Research Reports|May 24, 2023
Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLCQing Zhou, Ross A Soo, Gee-Chen Chang, et al.
The New England Journal of Medicine|June 4, 2013
Crizotinib versus chemotherapy in advanced ALK-positive lung cancerAlice T Shaw, Dong-Wan Kim, Kazuhiko Nakagawa, et al.
European Journal of Cancer (Oxford, England : 1990)|October 2, 2024
Potent covalent irreversible inhibitor of KRAS G12C IBI351 in patients with advanced solid tumors: First-in-human phase I studyQing Zhou, Nong Yang, Mingfang Zhao, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 11, 2020
Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal Circulating Tumor DNA Monitoring in Advanced EGFR-Mutant Lung Adenocarcinoma Under Gefitinib TreatmentJianchun Duan, JiaChen Xu, Zhijie Wang, et al.
BMC Medicine|May 28, 2025
Transarterial chemoembolization plus apatinib for unresectable hepatocellular carcinoma: a multicenter, randomized, open-label, phase III trialXue-Feng Kan, Bin Liang, Xiao-Lin Zhang, et al.
Pageof 153